Alnylam Pharmaceuticals (ALNY) Gross Profit (2018 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Gross Profit came in at $992.7 million in Q2 2026, up 57.16% YoY from $631.7 million in Q2 2025, and up 3.44% on a QoQ basis from $959.7 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Gross Profit (2018 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 9 years of Gross Profit data on file, last reported at $992.7 million in Q2 2026.
- Quarterly Gross Profit rose 57.16% year-over-year to $992.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.8 billion (up 155.4% YoY) and the FY2025 annual result came in at $3.0 billion, up 56.4% from the prior year.
- Gross Profit climbed to $992.7 million in Q2 2026, from $959.7 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $1.1 billion in Q3 2025 to a low of -$40.2 million in Q1 2025.
- A 5-year average of $490.2 million and a median of $429.3 million in 2024 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2025 — Gross Profit slumped 109.14% — and 2026, when it jumped 2488.21%.
- Tracing ALNY's Gross Profit over 5 years: stood at $288.9 million in 2022, then rose by 27.31% to $367.7 million in 2023, then surged by 33.39% to $490.5 million in 2024, then jumped by 69.07% to $829.3 million in 2025, then advanced by 19.7% to $992.7 million in 2026.
- The last three Gross Profit figures came in at $992.7 million (Q2 2026), $959.7 million (Q1 2026), and $829.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 992.69 Mn |
| Jun 30, 2026 | 992.69 Mn |
| Mar 31, 2026 | 959.66 Mn |
| Mar 31, 2026 | 959.66 Mn |
| Dec 31, 2025 | 829.31 Mn |
| Dec 31, 2025 | 829.31 Mn |
| Sep 30, 2025 | 1.05 Bn |
| Sep 30, 2025 | 1.05 Bn |
| Jun 30, 2025 | 631.66 Mn |
| Jun 30, 2025 | 631.66 Mn |
| Mar 31, 2025 | 524.01 Mn |
| Mar 31, 2025 | 524.01 Mn |
| Dec 31, 2024 | 490.52 Mn |
| Dec 31, 2024 | 490.52 Mn |
| Sep 30, 2024 | 418.94 Mn |
| Sep 30, 2024 | 418.94 Mn |
| Jun 30, 2024 | 592.55 Mn |
| Jun 30, 2024 | 592.55 Mn |
| Mar 31, 2024 | 439.72 Mn |
| Mar 31, 2024 | 439.72 Mn |